Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUnity Health Toronto
About this trial
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.
Eligibility criteria
Qualifiers
Age ≥ 18
Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days
confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and/or insulin.
Ability to provided informed consent or through their substitute decision maker
Disqualifiers
Type 1 DM
Use of a GLP-1-RA within 30 days prior to screening
Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening)
Confirmed pregnancy, women of childbearing potential
Trial design
Treatments tested in this trial
- Semaglutide Pen
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov